Pentwater Capital Management Reduces $73M in Atrium Therapeutics, Inc. ($RNA)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Pentwater Capital Management reduced its position in Atrium Therapeutics, Inc. ($RNA) by 90% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 602,649 shares of Atrium Therapeutics, Inc. after selling 5,423,851 shares during the quarter. Pentwater Capital Management's holdings in Atrium Therapeutics, Inc. were worth $8.11 million as of its most recent filing.
Atrium Therapeutics, Inc. Stock Down 1.4%
Shares of Atrium Therapeutics, Inc. ($RNA) traded around $13.45 on Sunday, down 1.4% for the day.
Atrium Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Get Atrium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RNA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.